Spyre Therapeutics, Inc. SYRE Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s interest income?
- Spyre Therapeutics, Inc. (SYRE) reported interest income of $7M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s interest income changed year-over-year?
- Spyre Therapeutics, Inc.'s interest income increased by 7.7% year-over-year, from $6.49M to $7M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s interest income?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s interest income has grown at a 286.9% compound annual growth rate (CAGR), from $111K to $24.89M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.